Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil prepares viral hepatitis strategy

This article was originally published in Clinica

Executive Summary

Brazil is close to completing a survey of cases of viral hepatitis A, B and C in each of its state capitals, in a bid to determine prevalence rates and risk factors, with a view to updating its prevention strategies. In the case of hepatitis A, the survey will cover the 5-19-year age range; the HBV and HCV surveys will target the 10-69 age range. The survey will comprise data from a total of 31,000 people. This week saw the launch of a survey of 1,700 people in Rio de Janeiro, which together with Sao Paulo (launched recently) and Espirito Santo and Minas Gerais (due to commence soon) comprise the state capitals of the South East region and some of the country's largest conurbations. The surveys for the remaining four, including the federal district (Brasilia), are all but complete.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel